palisadebio.com - PALI Year-over-year earnings per share growth for the last twelve months

Official company branding of Palisade Bio (PALI)

Palisade Bio, Inc. (PALI) focuses on treating intestinal pathologies, where the success of PALI-2108 for colitis and partnerships with industry behemoths serve as the primary catalysts. The quarterly EPS trajectory confirms the current trend, with the 82.60 mark serving as the relevant indicator. Prospects rely on innovative enzyme inhibitors, although stringent FDA requirements create certain risks until testing is completed.

Palisade Bio, Inc. (PALI) - Quarterly EPS earnings growth from 07/04/2022 to 11/13/2026

Summary analytical data breakdowns for Palisade Bio Inc. (PALI)

- share price and consensus valuation forecast:
Stock Quotes Palisade Bio|PALI - Analyst Forecast Prices
- issuer market value details:
Market Value Palisade Bio|PALI - Full Business Value
- book capitalization data:
Book Value per Share Palisade Bio|PALI - Book Capitalization|Market Value to Book Value Ratio palisadebio.com|PALI - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Palisade Bio, Inc.|PALI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Palisade Bio, Inc.|PALI - Company Total Debt Obligations|Debts to Book Capitalization Palisade Bio|PALI - Company Long-Term Debts|Company Short-Term Debts Palisade Bio|Quick Ratio palisadebio.com
- earnings and valuation multiples indicators:
PALI - Company Net Income|Future Profit Palisade Bio, Inc.|PALI - Company Value to Net Income|Forward P/E Multiple Palisade Bio|PALI - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Palisade Bio|PALI - Operating income before deduction of amortization|Earnings per share for the last twelve months Palisade Bio|PALI - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months palisadebio.com|PALI - Earnings per share increase in current year|Earnings growth forecast for next year Palisade Bio, Inc.
Analysis of all company metrics:Palisade Bio - PALI
Flagship merchandise of Palisade Bio, Inc.

This indicator measures the quarterly rate of change in earnings per share, allowing investors to assess the actual efficiency of capital generation. By analyzing the quarterly earnings per share growth rate, one can determine the extent to which Palisade Bio, Inc. (PALI) is converting its specialized pharmaceutical logistics optimization and surgical center supply chain controls into actual financial growth.

Competitor analysis

PHAT (Phathom Pharmaceuticals, Inc.) - Year-over-year net earnings per share growth for the last 12 months|TERN: Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months Ironwood Pharma|Curanex - Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth IMRN|Quarterly EPS earnings growth evokepharma.com (EVOK)|Year-over-year earnings per share growth for the last twelve months Entero Therapeutics ENTO|RedHill Biopharma Ltd - Year-over-year earnings per share growth for the last twelve months|Jaguar Animal Health - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Biora Therapeutics, Inc BIOR|Morphic Holding, Inc. (MORF) - Year-over-year earnings per share growth for the last twelve months